The hunt for new genes and polymorphisms that can control the response to drugs

Pharmacogenomics

Volumn 3, Issue 5, 2002, Pages 679-686

  Sheffield, Leslie J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Association study; Case control; CYP450; Microarray; Pharmacogenetics; Pharmacogenomics; Polymorphism; TDT

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DRUG METABOLIZING ENZYME; ESTROGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TACROLIMUS;

ARTICLE; BIOTECHNOLOGY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG METABOLISM; DRUG RESPONSE; DRUG TARGETING; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; VEIN THROMBOSIS;

ANIMALS; CYTOCHROME P-450 CYP2D6; GENES; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0036740844     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.3.5.679     Document Type: Article

References (44)

1. Wolf CR, Smith G, Smith RL: Science, medicine and the future: pharmacogenetics. Br. Med. J. 320, 987-990 (2000).
2. Roses AD: Pharmacogenetics and the practice of medicine. Nature 405, 857-865 (2000).
3. Sheffield LJ: Strategies to find new genes involved in drug metabolism. Curr Opin. Mol. Ther. 3, 579-584 (2001).
4. Ring HZ, Kroetz DL: Candidate gene approach for pharmacogenetic studies. Pharmacogenomics 3, 47-56 (2002).
5. Howard LA, Sellers EM, Tyndale RF: The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics 3, 185-199 (2002).
6. Roses AD: Pharmacogenetics. Hum. Mol. Genet. 10, 2261-2267 (2001).
7. Pettipher R, Cardon LR: The application of genetics to the discovery of better medicines. Pharmacogenomics 3, 257-263 (2002).
8. Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin. Gen. 56, 247-258 (1999).
9. Ameen M, Smith CH, Barker JN: Pharmacogenetics in clinical dermatology. Br. J. Dermatol. 146, 2-6 (2002).
10. Aardema MJ, MacGregor JT: Toxicology and genetic toxicology in the new era of 'toxicogenomics': impact of '-omics' technologies. Mutat. Res. 499, 13-25 (2002).
11. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR: Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylatrion (cytochrome P4502D6) phenotypes. Pharmacogenetics 1, 33-41 (1991).
12. Sachs C, Brockmoller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
13. Bradford LD: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3, 229-243 (2002).
14. Riley JH, Allan CJ, Lai E, Roses A: The use of single nucleotide polymorphisms in the isolation of common disease genes. Pharmacogenomics 1, 39-47 (2000).
15. McCarthy JJ, Hilfiker R: The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat. Biotechnol. 18, 505-508 (2000).
16. Raucy JL, Allen SW: Recent advances in P450 research. Pharmacogenomics J. 1, 178-186 (2001).
17. Daly AK, Brockmoller J, Broly F et al.: Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201 (1996).
18. Meehan RR Gosden JR, Rout D et al.: Human cytochrome P450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am. J. Hum. Genet. 42, 26-37 (1988).
19. Gonzalez FJ, Vilbois F, Hardwick JP et al.: Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2, 174-179 (1988).
20. Risch NJ: Searching for genetic determinants in the new millennium. Nature 405, 847-856 (2000).
21. Daly AK, Day CP: Candidate gene case-control association studies: advantages and potential pitfalls. Br. J. Clin. Pharmacol. 52, 489-499 (2001).
22. Weiss ST, Silverman EK, Palmer LJ: Case-control association studies in pharmacogenetics. Pharmacogenomics J. 1, 157-158 (2001).
23. Bacanu SA, Devlin B, Roeder K: The power of genomic control. Am. J. Hum. Genet. 66, 1933-1944 (2000).
24. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
25. Nebert DW, Menon AG: Pharmacogenomics, ethnicity and susceptibility genes. Pharmacogenomics J. 1, 19-22 (2001).
26. Perneger TV: What's wrong with Bonferroni adjustments? Br. Med. J. 316, 1236-1238 (1998).
27. Boehringer S, Epplen JT, Krawczak M: Genetic association studies of bronchial asthma-a need for Bonferroni correction? Hum. Genet. 107, 197 (2000).
28. Risch N, Teng J: The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases I. DNA pooling. Genome Res. 8, 1273-1288 (1998).
29. Davarsi A: MR genetic dissection of complex traits in a high density SNP map era. Am. J. Hum. Genet. 63(Suppl.), A229 (1999).
30. Teng J, Risch N: The relative power of family-based and case-control designs for linkage disequilibrium studies of complex human diseases. II. Individual genotyping. Genome Res. 9, 234-241 (1999).
31. Hosking LK, Boyd PR, Xu CF et al.: Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity. Pharmacogenomics J. 2, 165-175 (2002).
32. Herrington DM, Klein KP: Invited review: pharmacogenetics of oestrogen replacement therapy. J. Appl. Physiol. 91, 2776-2784 (2001).
33. Dressman MA, Walz TM, Lavedan C et al.: Genes that cocluster with oestrogen receptor alpha in microarray analysis of breast biopsies. Pharmacogenomics J. 1, 135-141 (2001).
34. Marton MJ, DeRisi JL, Bennett HA et al.: Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4, 1293-1301 (1998).
35. Monga M, Sausville EA: Developmental therapeutics programme at the NCI: molecular target and drug discovery process. Leukaemia 16, 520-526 (2002).
36. Lennon GG: High-throughput gene expression analysis for drug discovery. Drug Discov. Today 5, 59-66 (2000).
37. Ringner M, Peterson C, Khan J: Analyzing array data using supervised methods. Pharmacogenomics 3, 403 (2002).
38. Jain KK: Applications of biochip and microarray systems in pharmacogenomics. Pharmacogenomics 1, 289-307 (2000).
39. Friend SH: How DNA microarrays and expression profiling will affect clinical practice. Br. Med. J. 319, 1306-1307 (1999).
40. Winzeler EA Richards DR, Conway AR et al: Direct allelic variation scanning of the yeast genome. Science 281, 1194-1197 (1998).
41. Braxton S, Bedilion T: The integration of microarray information in the drug development process. Curr. Opin. Biotechnol. 9, 643-649 (1998).
42. Terwilliger JD, Weiss KM: Linkage disequilibrium mapping of complex disease: fantasy or reality? Curr. Opin. Biotechnol. 9, 578-594 (1998).
43. Kruglyak L: Prospects for whole-genome linkage disequilibrium, mapping of common disease genes. Nat. Genet. 22, 139-144 (1999).
44. Judson R, Stephens JC, Windemuth A: The predictive power of haplotypes in clinical response. Pharmacogenomics 1, 15-26 (2000).